// App-Quantinova.ai

3579.0 : A phase Ib study of oral Chk1 inhibitor LY2880070 as monotherapy in patients with advanced or metastatic cancer.

Researchers

Presenter

  • Wilson H. Miller

Principal Investigators

  • Quincy S. Chu

  • Nathaniel Bouganim

  • Derek J. Jonker

  • Gerald Batist

  • Najwa J Buhlaiga

  • Stephanie Lheureux

  • Jennifer L. Spratlin

  • Thierry Alcindor

  • Patricia S Smith

  • Joel Owen

  • Sara L. Zaknoen

  • John R. Stille

  • Caroline Fortier

  • Darcy Vincett

  • Amit M. Oza

Medical Centers

  • Segal Cancer Center/Jewish General Hospital, McGill University, Montreal, QC, Canada

  • Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

  • Department of Medical Oncology, McGill University Health Center, Montreal, QC, Canada

  • The Ottawa Hospital Research Institute, Ottawa, ON, Canada

  • Segal Cancer Center/Jewish General Hospital, McGill University, Montreal, QC, Canada

  • Montreal University, Montreal, QC, Canada

  • Princess Margaret Hospital, Toronto, ON, Canada

  • Alberta Health Services (AHS), Edmonton, Canada

  • McGill University Health Centre, Montreal, QC, Canada

  • Eli Lilly and Company, Indianapolis, IN

  • Cognigen Corporation, Buffalo, NY

  • Strategic Dev Consulting, Carlsbad, CA

  • Esperas Pharma Inc, Montreal, QC, Canada

  • Osmosis Research Inc., Toronto, ON, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Cytochrome P450 Family 2 Subfamily D Member 6

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Multiple Ascending Dose

  • Multicenteric

Phase

  • NA

Study Id's

  • NCT02632448

Sponsors

  • Esperas Pharma Inc.

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved